Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?Zacks Investment Research · Sep 10, 2026
Lilly Builds Neuroscience into a New Long-Term Growth DriverZacks Investment Research · Sep 8, 2026
Jim Cramer Isn't Sure If There's Upside In This Health Care StockBenzinga · Sep 3, 2026
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAIGuruFocus · Aug 28, 2026
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAIPRNewsWire · Aug 28, 2026
Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?GuruFocus · Aug 17, 2026Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.11 | -$0.09 | Beat |
| May 12, 2026 | -$0.11 | -$0.08 | Beat |
| Mar 6, 2026 | -$0.12 | -$0.05 | Beat |
| Nov 12, 2025 | -$0.12 | -$0.28 | Miss |
| Aug 14, 2025 | -$0.12 | -$0.14 | Miss |
| May 14, 2025 | -$0.19 | -$0.15 | Beat |